NCT03883412RecruitingPhase 4
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 18 Mar 2019
- Start date
- 28 Feb 2019
- Primary completion date
- Jun 2027
- Lead sponsor
- University of Virginia
- Diseases
- Type 2 diabetes
- NCT number
- NCT03883412
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 28 Feb 2019 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
- History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
- Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
- Known hypersensitivity to perflutren (contained in Definity)
Other
- Taking Insulin
- Smoking presently or in the past 6 months
- BP \>160/90
- BMI \>35
- Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
- Pregnant or breastfeeding.
Who the study is looking for
- Age 21-60
- A1C ≤ 8.5%
- Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
- On stable dose of oral hypoglycemic agents \>4 months
- On stable dose of other medications for \>4 months
Age in the registry: 21 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Coordinator of this site? Confirm its status | Charlottesville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.